Adverse drug reactions to treatments for XXXX : a retrospective chart review.

@entity1 @entity4766 @entity20497 @entity1910 @entity548 @entity799 @entity294 @entity344 @entity17577 @entity206 @entity1431 @entity6519 @entity207 @entity4765 @entity360 @entity3402
OBJECTIVE: This study evaluated the incidence and types of adverse drug reactions (ADRs) associated with medications used to treat active toxoplasmic @entity6519 . METHODS: This was a retrospective review of the clinical records of a consecutive series of @entity1 with active toxoplasmic @entity6519 , examined between March 1991 and August 1998. For inclusion in the review, @entity1 had to have been diagnosed with active toxoplasmic @entity6519 , been treated with a single drug or drug combination indicated for this condition, and been followed for at least 8 weeks. @entity1 who were lost to follow-up or who had incomplete chart data were excluded. Demographic data, pertinent aspects of the medical history, drug treatments, and ADRs associated with antitoxoplasmic treatment were recorded. RESULTS: Fifty-five @entity1 met the criteria for inclusion in the review. In descending order of frequency, they received antitoxoplasmic treatment with @entity3402 (n = 50), @entity4766 (n = 40), @entity4765 (n = 33), @entity206 - @entity207 (n = 16), and @entity20497 (n = 10), alone or in combination. Twenty-two @entity1 (40.0%) had a total of 27 ADRs. The most frequently occurring ADRs were @entity1910 (19 [34.5%]), mostly associated with @entity4766 (9/40 [22.5%]) and @entity3402 (6/50 [12.0%]), and @entity344 such as @entity294 (6 [10.9%]), stomach upset (6 [10.9%]), and @entity548 (1 [1.8%]), mostly associated with @entity3402 (5/50 [10.0%], 3/50 [6.0%], and 1/50 [2.0%], respectively). The incidence of ADRs associated with individual antitoxoplasmic drugs was 30.0% (3/10) for @entity20497 , 26.0% (13/50) for @entity3402 , 22.5% (9/40) for @entity4766 , 12.5% (2/16) for @entity799 , and 12.1% (4/33) for @entity4765 . There were 2 serious ADRs: @entity360 in a @entity1 treated with @entity3402 and @entity1431 in a @entity1 treated with @entity4765 . Twenty-five ADRs were reversed on drug discontinuation; the remaining 2 were mild and did not require drug discontinuation. CONCLUSIONS: The overall incidence of treatment-associated ADRs was high (40.0%) in these @entity1 with @entity17577 . The most frequently occurring ADRs were @entity1910 and @entity344 .
